What Ai Li Treats: Main Uses and Benefits

Ai Li (Irinotecan) is a specialized chemotherapy agent commonly used for managing the progression of several types of advanced and metastatic cancers. Its therapeutic goal is to support patients during difficult episodes and contribute to the management of their disease's progression. Irinotecan is used alone or in combination with other drugs.

The medication is applied across therapeutic domains involving aggressive cell proliferation. It is most relevant in conditions presenting with significant symptomatic burden, such as metastatic colorectal cancer (mCRC), advanced pancreatic ductal adenocarcinoma, and certain extensive-stage Small Cell Lung Cancer (SCLC). It is typically used in clinical settings that involve acute or unstable symptom patterns, such as initial therapy for metastatic disease or after a cancer has progressed following earlier treatment.

The main benefit provided is that the treatment generally plays a role in managing the severity of the disease and is relevant for easing the progression of the malignancy, which helps support general well-being and stability during this advanced disease state. The treatment may assist with managing the systemic burden associated with the disease. This supportive relief helps patients cope more steadily with symptom fluctuations.

---

Quick Fact: Managing Progressive Tumor Burden

Property	Description
Primary Indication	Metastatic Colorectal Cancer (mCRC)
Symptom Focus	Symptoms related to heightened physiological activity (malignant growth)
Patient Benefit	Helps maintain a sense of stability when symptoms are more noticeable

Regulatory References

1. National Cancer Institute (NCI) overview

Eligibility Map: Who can and cannot use Ai Li — official regulatory information

The eligibility for Ai Li (Irinotecan) is determined by strict criteria defined in official regulatory labeling, focusing on patient status, organ function, and genetic profile.

Eligibility scope

Scope	Statement (Strictly Regulatory Language)
Populations for whom use is allowed	Adult patients with confirmed malignancies for whom treatment is indicated and who possess adequate baseline organ function.
Populations for whom use is not recommended	The pediatric population (safety and effectiveness have not been established). Patients undergoing renal dialysis for kidney impairment.
Populations for whom use is contraindicated	Patients with known hypersensitivity to the formulation; breastfeeding women; and patients with severe hepatic impairment (bilirubin levels significantly above the upper limit of normal).
Age-related eligibility rules	Adult use is established. Older adults (ge 65 years) require close monitoring due to a greater risk for specific toxicities.
Eligibility-related restrictions	Individuals who are homozygous for the *UGT1A128 allele or who have specific comorbidities, such as bowel obstruction**, have restricted eligibility.
Pregnancy and lactation eligibility status	Pregnancy is a contraindication as use can cause fetal harm. Effective contraception must be used by patients of reproductive potential.

Eligibility classifications (high-level)

Classification	Statement (Strictly Regulatory Language)
Eligibility severity classification	Contraindicated (e.g., Hypersensitivity, Lactation, Severe Hepatic Impairment). Conditional Use (e.g., UGT1A1 Genotype, Moderate Hepatic Impairment).
Regulatory basis	Based on official Prescribing Information and pharmacogenetic guidance.

Connection to the overall eligibility profile

Official labeling defines Ai Li as restricted to the adult population and prohibits its use in patients with formal contraindications, notably severe liver dysfunction or specific co-administered medications. Use is conditional upon genotype testing for the UGT1A1*28 allele, which mandates closer surveillance or a modified regimen. This structure ensures adherence to population-specific safety profiles documented by regulatory authorities.

Ai Li (Irinotecan) is subject to specific regulatory constraints regarding its co-administration with other substances, primarily due to its metabolism by the enzymes CYP3A4 and UGT1A1. Official documents highlight combinations that must be avoided, those that alter drug concentration, and special considerations for certain patient populations.

Contraindicated Combinations

Classification	Interacting Substance(s)
Formal Contraindication	Live attenuated vaccines (e.g., Yellow Fever Vaccine)

Interactions Affecting Drug Exposure

The most significant interactions involve substances that modify the concentration of the active metabolite, SN-38, which is crucial for the drug's intended action. Co-administration with strong inducers or inhibitors is generally not recommended.

• Exposure-Decreasing Agents: Strong CYP3A4 Inducers (e.g., Rifampicin, Phenytoin) and the herbal product St. John's Wort are officially noted to cause a substantial decrease in SN-38 systemic exposure.
• Exposure-Increasing Agents: Strong CYP3A4 Inhibitors (e.g., Ketoconazole) and UGT1A1 Inhibitors (e.g., Atazanavir) are associated with an increase in SN-38 systemic exposure.

Procedural and Population Constraints

• Timing Requirement: When co-administered with Cetuximab, regulatory labels stipulate that Irinotecan must not be administered earlier than 1 hour after the completion of the Cetuximab infusion.
• Pharmacogenetic Constraint: Individuals who are homozygous for the UGT1A1*28* or 6 alleles** are noted in prescribing information to have a higher risk of toxicity due to genetically reduced clearance of SN-38.
• Disease State Constraint: Irinotecan treatment is contraindicated for patients with bilirubin levels above 3 times the Upper Limit of Normal (ULN) due to documented decreased clearance in hepatic impairment.

The action of Ai Li is governed by its specific engagement with the cell's DNA replication machinery, resulting in Topoisomerase I poisoning that culminates in programmed cell death.

Prodrug Activation and Target Specificity The compound Irinotecan functions as a prodrug, which means it must first be biologically converted by carboxylesterase enzymes into its highly active metabolite, SN-38. This metabolite is the functional agent that selectively targets DNA Topoisomerase I (Top1) . This initial enzymatic step controls the active drug's availability at the cellular level.

DNA Topoisomerase I Poisoning and Cascade SN-38 exerts its effect by binding directly to the transient complex formed when Top1 cleaves a single DNA strand to relieve strain. By stabilizing this complex, SN-38 prevents the re-sealing of the strand. This mechanism generates persistent single-strand interruptions throughout the genome, which is a key molecular step for the downstream cytotoxic effect. In rapidly dividing cells, when the Replication Fork encounters the trapped complex, the collision converts the single-strand interruption into a double-strand break, which is often inefficiently repaired. This damage induces cell cycle arrest and facilitates the initiation of Apoptosis (programmed cell death).

Mechanism Constraints The biological action of the mechanism is constrained by factors, notably the overexpression of drug efflux pumps like ABCG2 in target cells. These pumps actively remove the active metabolite, SN-38, from the cell, lowering its concentration at the nuclear target.

How Ai Li is Used: Administration Guidelines

Ai Li (Irinotecan) is administered following specific protocols, delivered only in specialized medical settings under the supervision of a qualified physician. All instructions for its use are based on body surface area (BSA) and defined treatment cycles.

Usage Parameter	Administration Details
Route of Administration	Exclusively by Intravenous Infusion (IV) into a peripheral or central vein.
Dosing Basis	Calculated per square meter (mg/m^2) of Body Surface Area (BSA).
Infusion Duration	The diluted solution is infused over a period of 30 to 90 minutes.

Standard Regimens (Adults)

Dosing recommendations may vary by region and combination therapy; the following are examples of established schedules:

• Monotherapy: A starting dose of 350 mg/m^2 is commonly administered once every three weeks.
• Combination Therapy: Regimens include 180 mg/m^2 once every two weeks, or 125 mg/m^2 weekly for four doses, followed by a two-week rest.

Preparation and Special Conditions

• Preparation: The medicine is supplied as a concentrate that must be diluted prior to infusion using either 5% Dextrose or 0.9% Sodium Chloride injection.
• Premedication: Instructions advise administering antiemetic agents to the patient at least 30 minutes before the infusion begins.
• Duration: Treatment may continue for additional cycles provided the individual continues to experience clinical benefit, and cycles are often delayed for 1–2 weeks to allow for recovery.

Population-Specific Dose Rules

Specific guidelines include instructions for dose modification in certain populations:

• Older Adults (70 years and above): A lower starting dose (e.g., 300 mg/m^2 instead of 350 mg/m^2) is recommended for the three-week schedule.
• Hepatic Impairment: Specific dose reductions (e.g., to 200 mg/m^2) are required if total bilirubin levels are elevated between 1.5 and 3 times the upper limit of normal.

These instructions establish a precise, procedural framework that dictates the preparation, route, schedule, and dose adjustments for the medicine.

Research evidence / Overview of studies for Ai Li

The understanding of Ai Li (irinotecan) is built upon an established base of clinical research, primarily involving large-scale randomized controlled trials (RCTs) and subsequent scientific meta-analyses. The research explored how this medicine, generally used in combination with other agents, was associated with changes in measured research outcomes.

Evidence for use in Metastatic Colorectal Cancer (mCRC)

Research for mCRC has explored the use of Ai Li as part of existing chemotherapy regimens. Studies were primarily designed as RCTs, which compared different drug combinations in adults with advanced disease.

These studies monitored key research outcomes, including Overall Survival (OS) and Progression-Free Survival (PFS), which track the measured research outcomes related to overall duration and progression-free duration, respectively. Research reports described patterns related to the measured values for OS, PFS, and ORR when compared against regimens that did not contain Ai Li. Findings described group patterns that have been summarized in subsequent scientific reviews.

Evidence for use in Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

The research for advanced PDAC has focused on the use of Ai Li as part of intensive combination regimens. The studies explored patient outcomes, mainly measuring research outcomes like Overall Survival and Progression-Free Survival, when this formulation was combined with agents like 5-fluorouracil. Research reports described measurements recorded in the studies when compared to control regimens. Because this condition is characterized by rapid progression, the reported follow-up durations for outcome measurements in the available evidence are typically short to intermediate-term.

What Research Gaps and Uncertainties Remain

The scientific understanding of Ai Li continues to evolve, and the evidence highlights several key limitations. For extensive-stage Small Cell Lung Cancer (SCLC), certain major trials reported mixed findings, which means that the research continues to explore which combination regimen provides the most consistent outcome measurements. There is limited information for long-term outcomes, as most clinical trials are designed to track specific disease-related endpoints over a finite period. Additionally, most RCTs enroll a highly selected patient group, which means the results apply only to the populations studied, and the outcome patterns in the general population may be observed differently.

Key Studies & References

1. Irinotecan plus cisplatin versus etoposide plus cisplatin in extensive-stage small-cell lung cancer: a multicenter phase III study

The storage and disposal of Ai Li (Irinotecan Hydrochloride) concentrate must follow strict regulatory guidelines to maintain its stability and ensure safe handling.

Official Storage Conditions

Requirement	Condition
Temperature	Store unopened vials at controlled room temperature (20 C to 25 C).
Prohibition	The product must not be frozen.
Protection	Keep the vial in the original carton to protect from light until use.

Handling and Disposal Rules

Ai Li must be kept out of the sight and reach of children. The concentrate should be inspected for precipitate; if crystals form and do not dissolve after shaking, the product must be discarded. Because Irinotecan is a cytotoxic agent, all unused product, expired vials, and related waste must be treated as hazardous medicinal waste and disposed of according to local regulations. It must not be disposed of in household waste or wastewater.